癌に関連した静脈性血栓栓塞栓症に対する抗血栓療法
Giacinto Di Leo1, Costanza Agata Bordonaro1, Davide Capodanno2
1Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. Rodolico-San Marco" University of, Catania, Italy.
まとめ
癌に関連した静脈血栓塞栓症 (VTE) は,がん患者の主要な死因です. 低分子量ヘパリンや直接投与される経口抗凝固剤のような現在の治療法には限界があり,新しい治療法が有望であることを示しています.
科学分野:
- 腫瘍学 腫瘍学
- 血液学 ヘマトロジ
- 薬理学 薬理学とは
背景:
- 癌に関連した静脈血栓栓塞栓症 (VTE) は,腫瘍学における頻繁な,生命を脅かす合併症であり,癌による死亡の第2の主要な原因としてランク付けされています.
- 病原生は,腫瘍の凝固活性,全身の炎症,および前血栓性抗がん療法を含むが,特定の癌および進行段階でリスクが高くなる.
研究 の 目的:
- 既定および新興の治療戦略を含む,がんに関連したVTEの現在の管理をレビューする.
- VTEを患っているがん患者の抗凝固薬における課題と満たされていないニーズを強調する.
- VTE管理を改善するために,XI因子阻害剤などの新薬の潜在能力を議論する.
主な方法:
- 癌に関連したVTE管理に関する現在の文献とガイドラインのレビュー.
- 低分子量ヘパリン (LMWHs) と直接口服抗凝固剤 (DOACs) の有効性と限界の分析.
- 新しい治療目標と進行中の臨床試験の探索,因子XI抑制を含む.
主要な成果:
- LMWHとDOACはファーストラインの選択肢ですが,出血のリスク,薬物相互作用,特定の患者グループでの管理 (例えば,血栓塞栓症など) などの課題があります.
- 抗凝固薬と治療の順守にもかかわらず,再発性血栓形成は,重要な満たされていないニーズが残っています.
- 新興戦略,特にXI因子抑制は,出血リスクの軽減とともに有効性の向上の可能性を示しています.
結論:
- 癌に関連したVTEの管理には,トランボシスと出血のリスクのバランスをとって,個別化されたアプローチが必要です.
- この脆弱な患者集団における持続的な課題に対処し,アウトカムを改善するために,新しい抗凝固戦略が必要である.
- アベラシマブのような薬剤の試験を含む進行中の研究は,治療プロトコルの改良に不可欠です.
関連する概念動画
01:29Venous Thrombosis III: Interprofessional Care
388
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
388
01:30Venous Thrombosis IV: Nursing Management
278
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
278
01:30Venous Thrombosis I: Introduction
504
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
504
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
362
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
362
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.5K
01:27Pulmonary Embolism III: Nursing Management
470
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
470